1xor
From Proteopedia
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
| - | Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze | + | Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases. We describe the high-resolution crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases. These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding. A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions. These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases. |
==Disease== | ==Disease== | ||
| Line 17: | Line 17: | ||
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
[[Category: Single protein]] | [[Category: Single protein]] | ||
| - | [[Category: Artis, D | + | [[Category: Artis, D R.]] |
[[Category: Bollag, G.]] | [[Category: Bollag, G.]] | ||
| - | [[Category: Card, G | + | [[Category: Card, G L.]] |
| - | [[Category: England, B | + | [[Category: England, B P.]] |
[[Category: Fong, D.]] | [[Category: Fong, D.]] | ||
[[Category: Gillette, S.]] | [[Category: Gillette, S.]] | ||
| - | [[Category: Ibrahim, P | + | [[Category: Ibrahim, P N.]] |
| - | [[Category: Kim, S | + | [[Category: Kim, S H.]] |
[[Category: Lee, B.]] | [[Category: Lee, B.]] | ||
[[Category: Luu, C.]] | [[Category: Luu, C.]] | ||
| - | [[Category: Milburn, M | + | [[Category: Milburn, M V.]] |
[[Category: Powell, B.]] | [[Category: Powell, B.]] | ||
[[Category: Schlessinger, J.]] | [[Category: Schlessinger, J.]] | ||
[[Category: Suzuki, Y.]] | [[Category: Suzuki, Y.]] | ||
[[Category: Tabrizizad, M.]] | [[Category: Tabrizizad, M.]] | ||
| - | [[Category: Zhang, K | + | [[Category: Zhang, K Y.J.]] |
[[Category: MG]] | [[Category: MG]] | ||
[[Category: ZAR]] | [[Category: ZAR]] | ||
| Line 41: | Line 41: | ||
[[Category: zardaverine]] | [[Category: zardaverine]] | ||
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 15:57:04 2008'' |
Revision as of 13:57, 21 February 2008
|
Catalytic Domain Of Human Phosphodiesterase 4D In Complex With Zardaverine
Contents |
Overview
Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases. We describe the high-resolution crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases. These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding. A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions. These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases.
Disease
Known disease associated with this structure: Stroke, susceptibility to, 1 OMIM:[600129]
About this Structure
1XOR is a Single protein structure of sequence from Homo sapiens with , and as ligands. Active as 3',5'-cyclic-nucleotide phosphodiesterase, with EC number 3.1.4.17 Full crystallographic information is available from OCA.
Reference
Structural basis for the activity of drugs that inhibit phosphodiesterases., Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY, Structure. 2004 Dec;12(12):2233-47. PMID:15576036
Page seeded by OCA on Thu Feb 21 15:57:04 2008
Categories: 3',5'-cyclic-nucleotide phosphodiesterase | Homo sapiens | Single protein | Artis, D R. | Bollag, G. | Card, G L. | England, B P. | Fong, D. | Gillette, S. | Ibrahim, P N. | Kim, S H. | Lee, B. | Luu, C. | Milburn, M V. | Powell, B. | Schlessinger, J. | Suzuki, Y. | Tabrizizad, M. | Zhang, K Y.J. | MG | ZAR | ZN | Pde | Pde4d | Phosphodiesterase | Zardaverine
